Lambda-carrageenan for COVID-19

Worldwide urbanization and subsequent migration have accelerated the emergence and spread of diverse novel human diseases. Among them, diseases caused by viruses could result in epidemics, typified by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which hit the globe towards the end of December 2019. The global battle against SARS-CoV-2 has reignited interest in finding alternative treatments for viral infections. The marine world offers a large repository of diverse and unique bioactive compounds. Over the years, many antiviral compounds from marine organisms have been isolated and tested in vitro and in vivo. However, given the increasing need for alternative treatment, in silico analysis appears to provide a time- and cost-effective approach to identifying the potential antiviral compounds from the vast pool of natural metabolites isolated from marine organisms. In this perspective review, we discuss marine-derived bioactive metabolites as potential therapeutics for all known disease-causing viruses including the SARS-CoV-2. We demonstrate the efficacy of marine-derived bioactive metabolites in the context of various antiviral activities and their in silico, in vitro, and in vivo capacities.

The World Health Organization (WHO) has classified COVID-19 as a pandemic infection due to the global spread of new corona virus infections. Due to this virus infection, millions of people all around the world had to die or endure severe disease. It will be crucial to find new therapeutic treatments in order to prepare for a similar viral pandemic in the future. Carrageenans have apparently been effective against 12 viruses, including SAR-COV-2. In this investigation, angiotensin-converting enzyme 2 (ACE2) and main protease (Mpro) were used as molecular targets for virtual screening of kappa-, lambda-, and iota- carrageenans. When compared to antiviral drugs, the results show that all three carrageenans have substantial binding affinity for ACE2 and Mpro. The binding affinity of iota-carrageenan is greater than that of other compounds. The binding affinity suggests that carrageenans could be utilized to produce potent antiviral drugs.